Skip to Content

Integrilin (eptifibatide) Disease Interactions

There are 2 disease interactions with Integrilin (eptifibatide):


GpIIb/IIIa platelet inhibitors (applies to Integrilin) bleeding risks

Major Potential Hazard, High plausibility. Applicable conditions: Brain/Intracranial Tumor, Thrombocytopathy, Cerebral Vascular Disorder, Hypertension, Coagulation Defect, Thrombocytopenia

The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3). Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy. Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.


  1. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP "Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion." Am J Cardiol 78 (1996): 1161
  2. Kleiman NS "Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis." Am J Cardiol 80 (1997): b29-33
  3. Adgey AA "An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors." Am Heart J 135 (1998): s43-55
  4. "Product Information. Aggrastat (tirofiban)." Merck & Co, Inc, West Point, PA.
  5. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ "Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery." Am J Cardiol 74 (1994): 1166-70
  6. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987): 703-13
  7. The RESTORE Investigators "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction..." Circulation 96 (1997): 1445-53
  8. The IMPACT-II Investigators "Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II." Lancet 349 (1997): 1422-8
  9. "Product Information. Integrilin (eptifibatide)." Schering Laboratories, Kenilworth, NJ.
View all 9 references

Eptifibatide (applies to Integrilin) renal dysfunction

Moderate Potential Hazard, High plausibility.

The use of eptifibatide is contraindicated in patients dependent of dialysis. Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min. Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients Clinical monitoring of renal function is recommended.


  1. "Product Information. Integrilin (eptifibatide)." Schering Laboratories, Kenilworth, NJ.

Integrilin (eptifibatide) drug interactions

There are 139 drug interactions with Integrilin (eptifibatide)

Integrilin (eptifibatide) alcohol/food interactions

There is 1 alcohol/food interaction with Integrilin (eptifibatide)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.